Kaur, H., Goodman, C., Thompson, E., Thompson, K.-A., Masanja, I., Kachur, S. P. and Abdulla, S. (2008) A nationwide survey of the quality of antimalarials in retail outlets in Tanzania. PloS one, 3 (10). ISSN 1932-6203
pone.0003403.pdf - Accepted Version
Restricted to Affiliated users only
Available under License Creative Commons Attribution Non-commercial.
Retail pharmaceutical products are commonly used to treat fever and malaria in sub-Saharan African countries. Small scale studies have suggested that poor quality antimalarials are widespread throughout the region, but nationwide data are not available that could lead to generalizable conclusions about the extent to which poor quality drugs are available in African communities. This study aimed to assess the quality of antimalarials available from retail outlets across mainland Tanzania.
METHODS AND FINDINGS
We systematically purchased samples of oral antimalarial tablets from retail outlets across 21 districts in mainland Tanzania in 2005. A total of 1080 antimalarial formulations were collected including 679 antifol antimalarial samples (394 sulfadoxine/pyrimethamine and 285 sulfamethoxypyrazine/pyrimethamine), 260 amodiaquine samples, 63 quinine samples, and 51 artemisinin derivative samples. A systematic subsample of 304 products was assessed for quality by laboratory based analysis to determine the amount of the active ingredient and dissolution profile by following the published United States Pharmacopoeia (USP) monogram for the particular tablet being tested. Products for which a published analytical monogram did not exist were assessed on amount of active ingredient alone. Overall 38 or 12.2% of the samples were found to be of poor quality. Of the antifolate antimalarial drugs tested 13.4% were found to be of poor quality by dissolution and content analysis using high-performance liquid chromatography (HPLC). Nearly one quarter (23.8%) of quinine tablets did not comply within the tolerance limits of the dissolution and quantification analysis. Quality of amodiaquine drugs was relatively better but still unacceptable as 7.5% did not comply within the tolerance limits of the dissolution analysis. Formulations of the artemisinin derivatives all contained the stated amount of active ingredient when analysed using HPLC alone.
Substandard antimalarial formulations were widely available in Tanzania at the time of this study. No products were detected that did not contain any amount of the stated active ingredient. Quinine and sulfadoxine/pyrimethamine products were the most widely available and also the most likely to be of poor quality. Substandard products were identified in all parts of the country and were labeled as made by both domestic and international manufacturers. With the expansion of the retail pharmaceutical sector as a delivery channel for antimalarial formulations the need for regular nationwide monitoring of their quality will become increasingly important.
|Keywords:||Pharmacy, malaria treatment, sub-saharan Africa, antimalaria, drug, Tanzania|
|Subjects:||Health Systems > Drugs, Medical Supplies & Logistics
Malaria > Surveillance, monitoring, evaluation
|Divisions:||Ifakara Health Institute > Biomedical|
|Depositing User:||Mr Joseph Madata|
|Date Deposited:||25 Jul 2012 21:49|
|Last Modified:||16 Aug 2012 15:57|
Actions (login required)
Downloads per month over past year